Bringing the fundamentals into focus…
Back to Tarsus Pharmaceuticals, Inc.
How Tarsus Pharmaceuticals, Inc. stacks up
TARS · against 552 other Healthcare companies listed in US-listed
Overall
48/ 100
Above the middle of the pack.
Ranked #214 of 553 · scores higher than 60% of peers
Bars: peers in each 10-point band of the overall score101 peers with an overall score of 40–49, including TARS · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around TARS| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 595M USD | 97 | 96 | 98 | 99 | 0 / 2 | |
| 1 | 261M USD | 97 | 93 | — | 98 | 0 / 2 | |
| 3 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 609M USD | 91 | 95 | 99 | 99 | 0 / 2 | |
| 214 | 650M USD | 48 | 8 | 81 | 16 | 0 / 2 | |
| 214 | 2.2B USD | 48 | 33 | — | 11 | 0 / 2 | |
| 214 | 3.8B USD | 48 | 8 | 90 | 4 | 0 / 2 | |
| 214 | 1.6B USD | 48 | 53 | 50 | 28 | 1 / 2 | |
| 214 | 3.4B USD | 48 | 8 | 96 | 28 | 1 / 2 | |
| 214 | 1.3B USD | 48 | 60 | 51 | 59 | 2 / 2 | |
| 221 | 3.9B USD | 47 | 8 | 84 | 10 | 0 / 2 | |
| 221 | 54.0B USD | 47 | 57 | 45 | 53 | 2 / 2 | |
| 221 | 116.9B USD | 47 | 70 | 49 | 44 | 2 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score